Tumor location: prognostic or predictive marker in metastatic colorectal cancer?

Over the last decade, evidence has proven that by identifying particular biomarkers in metastatic colorectal cancer (mCRC) patients’ tumor, treatment decisions can be made to ensure that patients receive the most effective treatment for them.

Investigators from a recent retrospective subanalyses observed that patients with mCRC had different treatment outcomes based on the location of their tumor. But is this truly a predictive marker that should inform treatment?

Professor Julien Taieb, a leading medical oncologist, discusses whether these data will now impact the way physicians select treatment for their mCRC patients, and what the future holds for personalized medicine in mCRC.